DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: amprenavir

Summary for Generic Name: amprenavir

Tradenames:1
Patents:4
Applicants:1
NDAs:2
Drug Master File Entries: see list4
Formulation / Manufacturing:see details

Clinical Trials for: amprenavir

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
Status: Completed Condition: HIV Infections

Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
Status: Terminated Condition: HIV Infections

A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients
Status: Completed Condition: HIV Infections

An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen
Status: Completed Condition: HIV Infections

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
Status: Completed Condition: HIV Infections

A Study of Amprenavir in HIV-Infected Patients
Status: Completed Condition: HIV Infections

A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications
Status: Completed Condition: HIV Infections

Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients
Status: Active, not recruiting Condition: HIV Infections

Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz
Status: Completed Condition: HIV Infection

Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.
Status: Completed Condition: HIV Infections

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxosmithkline
AGENERASE
amprenavir
SOLUTION;ORAL021039Apr 15, 1999DISCNNo5,585,397<disabled>
Glaxosmithkline
AGENERASE
amprenavir
SOLUTION;ORAL021039Apr 15, 1999DISCNNo5,723,490<disabled>TREATMENT OF HIV INFECTION
Glaxosmithkline
AGENERASE
amprenavir
SOLUTION;ORAL021039Apr 15, 1999DISCNNo5,646,180<disabled>TREATMENT OF HIV INFECTION
Glaxosmithkline
AGENERASE
amprenavir
CAPSULE;ORAL021007Apr 15, 1999DISCNNo5,585,397<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc